Cargando…

Identification of FDA Approved Antiviral Drugs for COVID-19 Treatment using Unbiased Virtual Screening

Detalles Bibliográficos
Autores principales:	Greer, Rory, Song, Yuwei, Patton, Michael J., Might, Matthew, Harrod, Kevin, Petit, Chad M., Song, Yuhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Biophysical Society 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879731/ http://dx.doi.org/10.1016/j.bpj.2020.11.1394

Ejemplares similares

Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs
por: Gu, Shuo, et al.
Publicado: (2018)

Virtual Screening of FDA-Approved Drugs for Enhanced Binding with Mitochondrial Aldehyde Dehydrogenase
por: Zhou, Boqian, et al.
Publicado: (2022)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2
por: Detroja, Trishna Saha, et al.
Publicado: (2022)

Fully automated virtual screening pipeline of FDA-approved drugs using Caver Web
por: Musil, Milos, et al.
Publicado: (2022)

Review on fluorinated nucleoside/non-nucleoside FDA-approved antiviral drugs
por: Ismail, Magda M. F., et al.
Publicado: (2022)

Virtual Screening of FDA-Approved Drugs against LasR of Pseudomonas aeruginosa for Antibiofilm Potential
por: Sadiq, Suhaib, et al.
Publicado: (2020)

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2
por: Liang, Hualou, et al.
Publicado: (2021)

Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals
por: Mousavi Maleki, Masoumeh Sadat, et al.
Publicado: (2022)

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
por: Jeon, Sangeun, et al.
Publicado: (2020)

Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: a high throughput virtual screening study
por: Srivastava, Varshita, et al.
Publicado: (2023)

The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
por: Jasenosky, Luke D., et al.
Publicado: (2019)

Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library
por: Wang, Peilin, et al.
Publicado: (2018)

Zika antiviral chemotherapy: identification of drugs and promising starting points for drug discovery from an FDA-approved library
por: Pascoalino, Bruno S., et al.
Publicado: (2016)

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
por: Park, Su-Jin, et al.
Publicado: (2020)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs
por: Sun, Ren, et al.
Publicado: (2013)

Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
por: Tompa, Dharma Rao, et al.
Publicado: (2021)

Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme
por: Bahadur Gurung, Arun, et al.
Publicado: (2020)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach
por: Zhang, Yiming, et al.
Publicado: (2021)

Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
por: Afzaal, Hasan, et al.
Publicado: (2022)

High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses
por: Ding, Cuiling, et al.
Publicado: (2022)

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection
por: Wang, Shaobo, et al.
Publicado: (2017)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening
por: Jade, Dhananjay, et al.
Publicado: (2022)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
por: Madrid, Peter B., et al.
Publicado: (2013)

FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
por: Mei, Yikun, et al.
Publicado: (2020)

Network model‐based screen for FDA‐approved drugs affecting cardiac fibrosis
por: Zeigler, Angela C., et al.
Publicado: (2021)

Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury
por: Li, Haixia, et al.
Publicado: (2023)

FDA-Approved Drug Screening for Compounds That Facilitate Hematopoietic Stem and Progenitor Cells (HSPCs) Expansion in Zebrafish
por: Feng, Zhi, et al.
Publicado: (2021)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_260s05a19989vfip8hfvr8lq8e